HYRIMOZ 80 MG / 0.8 ML

What is HYRIMOZ?

HYRIMOZ 80 MG / 0.8 ML contains ADALIMUMAB : 80 MG / 0.8 ML. It is listed in the Health Canada Drug Product Database under DIN 02542366, held by SANDOZ CANADA INCORPORATED, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 17-Apr-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is HYRIMOZ used for?

Hyrimoz is indicated for reducing the signs and symptoms, inducing major clinical response and clinical remission, inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis; in combination with methotrexate, reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients, 2 years of age and older; reducing the signs and symptoms of active arthritis and inhibiting the progression of structural damage and improving the physical function in adult psoriatic arthritis patients; reducing signs and symptoms in adult patients with active ankylosing spondylitis; reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn’s disease; reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 13 to 17 years of age weighing ≥ 40 kg with severely active Crohn’s disease; treatment of adult patients with moderately to severely active ulcerative colitis; inducing and maintaining clinical remission in pediatric patients 5 years of age and older with moderately to severely active ulcerative colitis; treatment of active moderate to severe hidradenitis suppurativa in adult and adolescent patients (12 to 17 years of age weighing ≥ 30 kg); treatment of adult patients with chronic moderate to severe plaque psoriasis; treatment of non-infectious uveitis (intermediate, posterior and panuveitis) in adult patients; treatment of chronic non-infectious anterior uveitis in pediatric patients from 2 years of age.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

How is it stored and handled?

null

How is it supplied?

20 mg in 0.4 mL sterile solution (50 mg/mL) subcutaneous injection in pre-filled syringe 40 mg in 0.8 mL sterile solution (50 mg/mL) subcutaneous injection in a pre-filled syringe 40 mg in 0.8 mL sterile solution (50 mg/mL) subcutaneous injection in a pre-filled autoinjector 20 mg in 0.2 mL sterile solution (100 mg/mL) subcutaneous injection in a pre-filled syringe 40 mg in 0.4 mL sterile solution (100 mg/mL) subcutaneous injection in pre-filled syringe 80 mg in 0.8 mL sterile solution (100 mg/mL) subcutaneous injection in pre-filled syringe 40 mg in 0.4 mL sterile solution (100 mg/mL) subcutaneous injection pre-filled autoinjector 80 mg in 0.8 mL sterile solution (100 mg/mL) subcutaneous injection pre-filled autoinjector

What can be used instead?

Other Canadian products sharing ATC code L04AB04 ADALIMUMAB. 34 of 41 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

Who else supplies ADALIMUMAB worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. ADALIMUMAB appears in 3291 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.